Mountain View, CA, United States of America

Darrin Anthony Lindhout

This inventor holds 27 USPTO granted patents and 15 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Metabolic Disorders. Top assignee: Ngm Biopharmaceuticals, Inc.. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Darrin Anthony Lindhout. Retrieved from https://idiyas.com/inventor/darrin-anthony-lindhout

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 15)

% Patents Active = 59.3

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 14)

Average Co-Inventor Count = 2.6

ph-index = 13

Forward Citations = 420(Granted Patents)

Company Filing History:

27 out of 73

Ngm Biopharmaceuticals, Inc.

patents

Years Active: 2015-2024

Loading Chart...

Areas of Expertise:

FGF19 Polypeptides

Diabetes Treatment

Metabolic Disorders

Hyperglycemic Conditions

Body Mass Reduction

Pharmaceutical Compositions

Fusion Variants

GDF15 Mutein Polypeptides

Glucose Levels

Compositions

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12173060 - Compositions and methods of use for treating metabolic disorders (2024-12-24),

2. 11530260 - Compositions and methods of use for treating metabolic disorders (2022-12-20),

3. 11358995 - Compositions and methods of use for treating metabolic disorders (2022-06-14),

4. 11066454 - Compositions comprising variants and fusions of FGF19 polypeptides (2021-07-20),

5. 11065302 - Compositions comprising fusion variants of FGF19 polypeptides (2021-07-20),

6. 10869909 - Compositions and methods of use for treating metabolic disorders (2020-12-22),

7. 10758590 - Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes (2020-09-01),

8. 10610568 - Compositions and methods of use for treating metabolic disorders (2020-04-07),

9. 10562965 - Compositions and methods of use for treating metabolic disorders (2020-02-18),

10. 10517929 - Pharmaceutical compositions comprising FGF19 variants (2019-12-31),

11. 10413590 - Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject (2019-09-17),

12. 10398758 - Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions (2019-09-03),

13. 10323075 - Compositions and methods of use for treating metabolic disorders (2019-06-18),

14. 10195250 - Compositions and methods of use for treating metabolic disorders (2019-02-05),

15. 9963494 - Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject (2018-05-08),

Title: **Innovative Contributions of Darrin Anthony Lindhout in Metabolic Disorder Treatments**

Introduction

Darrin Anthony Lindhout, based in Mountain View, CA, has made significant strides in the field of biopharmaceuticals with a focus on innovative treatments for metabolic disorders. With 27 patents to his name, his work exemplifies a commitment to addressing prevalent health challenges through cutting-edge research and development.

Latest Patents

Lindhout's latest contributions include innovative compositions and methods for treating metabolic disorders. Notably, he has developed a complex comprising a GDF15 polypeptide which plays a vital role in the methods aimed at treating individuals with glucose metabolism disorders and body weight issues. These patents exemplify a pioneering approach to enhancing therapeutic options for patients suffering from these conditions.

Career Highlights

Darrin is a key member of Ngm Biopharmaceuticals, Inc., where he leverages his expertise to drive advancements in metabolic health treatments. His extensive patent portfolio reflects his prolific contributions to biopharma research, underpinning numerous projects aimed at revolutionizing treatment protocols.

Collaborations

Throughout his career, Lindhout has partnered with innovative minds such as Lei Ling and Raj Haldankar. These collaborations enhance the depth and breadth of research at Ngm Biopharmaceuticals and are indicative of a team-focused approach to scientific discovery and innovation.

Conclusion

Darrin Anthony Lindhout stands out as an influential figure in the landscape of biopharmaceutical innovations, specifically in the realm of metabolic disorder treatments. His dedication to research and development continues to pave the way for new therapeutic avenues that hold promise for patients grappling with metabolic challenges.

Profile summary based on public USPTO records.